Well... fire up the laugh machines. Celgene went for $74 billion, turned $15.3b in revenue last year (2018 - don't have 2019 yet to my knowledge). I'm not going to dither with worldwide revenue predictions on cancer (not to mention HIV, GvHD, NASH, maybe MS, maybe who knows what else...), but let's just say that if we're fully diluted at 700mm shares, $50 is $35b. I think it's clear that the potential here could easily support such a deal, or more.

Also, put me squarely in the camp of "give me a BO". I don't think a BO would go for less than what would constitute a life-changing amount for me, given my investment. Not if cancer data keeps up, to once more say nothing of NASH. I don't want to have to time the market, and the immediate difference between what I do with my life currently and what I would do with my life if I had 8 figures in the bank is worth giving up some modicum of upside in the long run. Plus, by the time anything could close, I'll be either 100% LTCG or Roth.

And IndexGuy... I feel you on the productivity front. Pretty sure I damn near lost my job for real when I first got involved with CYDY back in early 2017. It's really difficult to be good at your job when you spend no time doing it.